• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

SAGES

Reimagining surgical care for a healthier world

  • Home
    • COVID-19 Annoucements
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Who is SAGES?
    • SAGES Mission Statement
    • Advocacy
    • Strategic Plan, 2020-2023
    • Committees
      • Request to Join a SAGES Committee
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Full Committee Rosters
      • SAGES Past Presidents
    • Donate to the SAGES Foundation
    • Awards
      • George Berci Award
      • Pioneer in Surgical Endoscopy
      • Excellence In Clinical Care
      • International Ambassador
      • IRCAD Visiting Fellowship
      • Social Justice and Health Equity
      • Excellence in Community Surgery
      • Distinguished Service
      • Early Career Researcher
      • Researcher in Training
      • Jeff Ponsky Master Educator
      • Excellence in Medical Leadership
      • Barbara Berci Memorial Award
      • Brandeis Scholarship
      • Advocacy Summit
      • RAFT Annual Meeting Abstract Contest and Awards
  • Meetings
    • NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2024 Scientific Session Call For Abstracts
      • 2024 Emerging Technology Call For Abstracts
    • CME Claim Form
    • Industry
      • Advertising Opportunities
      • Exhibit Opportunities
      • Sponsorship Opportunities
    • Future Meetings
    • Past Meetings
      • SAGES 2022
      • SAGES 2021
    • Related Meetings Calendar
  • Join SAGES!
    • Membership Benefits
    • Membership Applications
      • Active Membership
      • Affiliate Membership
      • Associate Active Membership
      • Candidate Membership
      • International Membership
      • Medical Student Membership
    • Member News
      • Member Spotlight
      • Give the Gift of SAGES Membership
  • Patients
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Patient Information Brochures
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find a SAGES Member
  • Publications
    • SAGES Stories Podcast
    • SAGES Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Patient Information Brochures
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • SCOPE – The SAGES Newsletter
    • COVID-19 Annoucements
    • Troubleshooting Guides
  • Education
    • OpiVoid.org
    • SAGES.TV Video Library
    • Safe Cholecystectomy Program
      • Safe Cholecystectomy Didactic Modules
    • Masters Program
      • SAGES Facebook Program Collaboratives
      • Acute Care Surgery
      • Bariatric
      • Biliary
      • Colorectal
      • Flexible Endoscopy (upper or lower)
      • Foregut
      • Hernia
      • Robotics
    • Educational Opportunities
    • HPB/Solid Organ Program
    • Courses for Residents
      • Advanced Courses
      • Basic Courses
    • Video Based Assessments (VBA)
    • Robotics Fellows Course
    • MIS Fellows Course
    • Facebook Livestreams
    • Free Webinars For Residents
    • SMART Enhanced Recovery Program
    • SAGES OR SAFETY Video
    • SAGES at Cine-Med
      • SAGES Top 21 MIS Procedures
      • SAGES Pearls
      • SAGES Flexible Endoscopy 101
      • SAGES Tips & Tricks of the Top 21
  • Opportunities
    • NEW-Area of Concentrated Training Seal (ACT)-Advanced Flexible Endoscopy
    • SAGES Fellowship Certification for Advanced GI MIS and Comprehensive Flexible Endoscopy
    • Multi-Society Foregut Fellowship Certification
    • SAGES Research Opportunities
    • Fundamentals of Laparoscopic Surgery
    • Fundamentals of Endoscopic Surgery
    • Fundamental Use of Surgical Energy
    • Job Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
  • Store
    • “Unofficial” Logo Products
  • Log In

A Phase I/IIa Clinical Trial of an Autologous Tumor/Dendritic Cell Fusion (Dendritoma) Vaccine with Low Dose Interleukin-2 in Stage IV Melanoma

Julia M Greene MD, BSc1, Erika J Schneble Md1, Xianzhong Yu2, Thomas E Wagner PhD2, George E Peoples3. 1San Antonio Military Medical Center, 2Perseus PCI, 3Cancer Insight

BACKGROUND: Stage IV melanoma has a high mortality rate. Traditional systemic therapies have shown limited benefit; however, several immunotherapies including cytokine therapies and checkpoint inhibitors have shown promise. Unfortunately, these immunotherapies are effective in only a small number of patients (pts), are non-specific and often toxic. We investigated a non-toxic and active specific form of immunotherapy, our dendritoma vaccine (DV), in late stage melanoma pts in a phase I/IIa trial.

METHODS: Autologous tumor and dendritic cells are fused, and sorted to create a DV for each stage IV melanoma pt. In the phase I, 10 pts were vaccinated every 3mos with doses of 0.5-1.0×106 DV. IL-2 was initiated on day 1 after vaccination, and increased from 3-9MIU/m2/day as tolerated for 5 days. In the phase IIa, 15 pts were vaccinated with doses from 0.25-1.0×106 DV every 6 wks up to 6 inoculations. IL-2 (3MIU/m2/day) was given on days 1, 3, and 5 after vaccination.

RESULTS: In the combined phase I/IIa trials (n=25), there were no grade 3-5 toxicities. There was a 24% pCR, and a 32% overall survival (OS) rate at 5 yrs. The median OS was 16.1mos compared to a historical 8.5mos. An increase in OS (75% vs 23.8%, p=0.065) was seen in pts with stage IV resected disease (n=4) versus all others and in pts receiving >3 vs <3 inoculations (45.5% vs 21.4%, p=0.07). Comparing phase I and IIa, there were no differences in pt characteristics (all p>0.1) yet median OS of phase I pts was 8.7mos vs 21.5mos for phase II pts. There was a higher dose of IL-2 and higher DV dose (710,983 vs 402,540 dendritomas (p=0.0006)) in the phase I but more frequent dosing and higher mean number of inoculations (3 vs 2.3 p=0.27) in the phase IIa.

CONCLUSIONS: The dendritoma vaccine potentially provides a clinical benefit without toxicity. There was an apparent dose response for inoculation number but not dose of the DV. Patients with resected stage IV disease benefited most. We have initiated a phase IIb trial in stage III/IV (resected) melanoma pts in the adjuvant setting to prevent recurrence.

57

Share this:

  • Twitter
  • Facebook
  • LinkedIn
  • Pinterest
  • WhatsApp
  • Reddit

Related

« Return to SAGES 2015 abstract archive

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064
1-310-437-0544
sagesweb@sages.org
Monday - Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Facebook
  • Twitter
  • YouTube

Important Links

SAGES 2023 Meeting Information

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals

 

  • taTME Study Info
  • Foundation
  • SAGES.TV
  • MyCME
  • Educational Activities

Copyright © 2023 Society of American Gastrointestinal and Endoscopic Surgeons